Vanda Pharmaceuticals (VNDA) Income from Continuing Operations (2010 - 2026)
Vanda Pharmaceuticals (VNDA) reported Income from Continuing Operations of 48524000.0 for Q1 2026, down 64.52% on a YoY basis from 136770532.87 in Q1 2025, and up 65.63% sequentially from 141187000.0 in Q4 2025.
Vanda Pharmaceuticals (VNDA) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals (VNDA) has 17 years of Income from Continuing Operations data on file, last reported at 48524000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 64.52% year-over-year to 48524000.0; the trailing twelve-month figure through Mar 2026 stood at 239488000.0 (down 441.44% YoY), and the FY2025 full-year result was 220474000.0, down 1066.53% from the prior year.
- Income from Continuing Operations climbed to 48524000.0 in Q1 2026, from 141187000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 6861000.0 in Q4 2022 to a low of 141187000.0 in Q4 2025.
- A 5-year average of 16420705.88 and a median of 4518000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations jumped 149.94% in 2023 and slumped 4000.73% in 2024, its largest moves.
- Tracing VNDA's Income from Continuing Operations over 5 years: stood at 6861000.0 in 2022, then sank by 134.85% to 2391000.0 in 2023, then slumped by 103.93% to 4876000.0 in 2024, then plunged by 2795.55% to 141187000.0 in 2025, then jumped by 65.63% to 48524000.0 in 2026.
- Business Quant data shows VNDA's Income from Continuing Operations at 48524000.0 in Q1 2026, 141187000.0 in Q4 2025, and 22590000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Vanda Pharmaceuticals | 309.49 Mn | 107.18 Mn | 48.56 Mn | -48.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.52 Mn |
| Dec 31, 2025 | -141.19 Mn |
| Sep 30, 2025 | -22.59 Mn |
| Jun 30, 2025 | -27.19 Mn |
| Mar 31, 2025 | -29.49 Mn |
| Dec 31, 2024 | -4.88 Mn |
| Sep 30, 2024 | -5.34 Mn |
| Jun 30, 2024 | -4.52 Mn |
| Mar 31, 2024 | -4.15 Mn |
| Dec 31, 2023 | -2.39 Mn |
| Sep 30, 2023 | 137,000.00 |
| Jun 30, 2023 | 1.49 Mn |
| Mar 31, 2023 | 3.23 Mn |
| Dec 31, 2022 | 6.86 Mn |
| Sep 30, 2022 | 3.26 Mn |
| Jun 30, 2022 | 2.59 Mn |
| Mar 31, 2022 | -6.46 Mn |
| Dec 31, 2021 | 7.08 Mn |
| Sep 30, 2021 | 7.72 Mn |
| Jun 30, 2021 | 9.65 Mn |